Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs TransMedics Group Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.52 (market cap $746.48M), while TransMedics Group Inc trades at $78.2 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 3.7× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and TransMedics Group Inc for 24 Days on average.
| FEPI | TMDX | |
|---|---|---|
Market Cap | $746.48M | $2.74B |
Volume | 334,337 | 949,331 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $150.42 |
52-Week Low | $37.98 | $61.99 |
Typical Hold Time | 56 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.51, down 0.18% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on concentrated AI and mega-cap tech holdings, generating high weekly distributions averaging $0.20-0.21. Recent articles highlight its 25% trailing yield but note capped upside potential and underperformance versus peers in total return during tech rallies.
The outlook balances high income generation against significant risk from tech concentration and volatility dependence. While the covered call strategy funds substantial dividends, it limits capital appreciation during market upswings. Key risks include drawdown vulnerability if tech stocks decline and competitive pressure from higher-performing income alternatives. Analyst sentiment remains cautious due to the trade-off between yield and total return potential.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
